The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
 
Dirk Arnold
Employment - Asklepios Kliniken
Honoraria - Amgen; AstraZeneca; Boston Scientific; Bristol-Myers Squibb; Eisai Europe; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen Oncology; Merck Serono; Merck Sharp and Dome; Pierre Fabre; Sanofi/Regeneron; Seagen; SERVIER; Sirtex Medical; Takeda; TERUMO; Viatris
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology
Research Funding - Oncolytics (Inst)
Travel, Accommodations, Expenses - Boston Scientific
(OPTIONAL) Uncompensated Relationships - Deputy Editor Clin Colorectal Cancer; ESMO; ESMO Open
 
Houra Loghmani
Employment - Oncolytics; Oncolytics
Stock and Other Ownership Interests - Oncolytics
 
Karol Cheetham
Stock and Other Ownership Interests - Oncolytics
 
Richard Trauger
No Relationships to Disclose
 
Thomas Charles Heineman
Employment - Oncolytics
Leadership - Oncolytics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Halozyme; Johnson & Johnson/Janssen; Merck; Oncolytics; Pfizer; Takeda
Patents, Royalties, Other Intellectual Property - Halozyme: PCT/US19/32537 Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble PH20 Genocea: PCT/US 62/855,309; PCT/US 62/848,527 Methods of identifying and/or selecting antigens that improve, increase and/or s
Travel, Accommodations, Expenses - Oncolytics